Global Scans · Diabetes · Weekly Summary

• [New] The new Dexcom Stelo Glucose Biosensor System, which will be available by summer, is intended for people 18 years and older who have type 2 diabetes but do not take insulin. www.PhysiciansWeekly.com
• [New] A range of major therapeutic areas - including diabetes, cardiovascular disease, immunology, oncology, and pain management - will see widely prescribed drugs lose patent protection in 2026. Drug Discovery News Magazine
• FDA approves Ozempic for a new indication: reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. GoalBMI Wellness
• FDA approves Rybelsus, the first oral semaglutide tablet for type 2 diabetes management - proving that the GLP-1 mechanism could be effective in pill form and setting up the later oral Wegovy development. GoalBMI Wellness
• Red blood cells at high elevations absorb large amounts of glucose, explaining the lower diabetes risk in mountain-dwelling populations. Yahoo News
• The Trump administration has proposed steep cuts of $5.78 billion to the National Institutes of Health for 2027, which could make it difficult for researchers and scientists to get funding, start new projects, and conduct long-term research to advance the field of diabetes care. diaTribe
• Approximately 589 million adults (20-79 years) were living with diabetes in 2024, with the figure projected to reach 853 million by 2050. MarkNtel Advisors
• Enrollees are not eligible if they already receive GLP-1 medications through their Medicare Part D drug plan or have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease (which might make them eligible for coverage through Part D). KCRA
• The inclusion of people with prediabetes represents an effort to prevent diabetes in the Medicare population, which will ultimately reduce healthcare costs nationally. CNBC
• People who ate high amounts of animal protein - and, as a result, also consumed a high amount of methionine and other essential amino acids - were more likely to be obese and had double the risk of type 2 diabetes than individuals who ate little to no animal protein. Refractor
• Researchers are taking a closer look at how different types of dietary fat may influence the risk of type 2 diabetes, a disease that affects millions of people worldwide and is linked to serious health complications and premature death. ScienceDaily
• By managing weight, people can lower their risk of developing diabetes, heart disease, liver disease and cancer. Wbur
• More than 640 million adults are projected to live with diabetes globally by 2030, increasing the need for routine wound-care solutions. Persistence Market Research
• Under the GLP-1 Bridge Program, Medicare will cover Wegovy specifically for weight loss - not just for diabetes management. Pound of Cure Weight Loss
• In the PAD Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) program, 30% of people aged 50-69 years with a history of cigarette smoking or diabetes, or aged > = 70 years regardless of risk factors, had PAD (223). PubMed Central (PMC)
• The number of people with diabetes will reach 783 million by 2045, creating a vast and expanding patient cohort requiring continuous medication supply, directly translating into compounding pharmacy revenue growth across all channels, including retail, hospital, and online platforms. Persistence Market Research
• CMS will reimburse device companies for wearables and app use with upfront payments for Medicare beneficiaries with, among others, chronic musculoskeletal pain, depression, diabetes and high blood pressure. Forbes
• The CDC reports that more people living with disabilities than without have risk factors such as obesity, heart disease, and diabetes. Financial Planning Association
• By 2050, the world will see over 853 million diabetes patients. Precedence Research
• The formulation development & fill-finish services segment is expected to grow at the fastest CAGR in the coming years, owing to the increasing need for injectable peptide therapies, such as GLP-1 receptor agonists for diabetes and obesity. Precedence Research
• Patients treated for type 2 diabetes lost an average of 4.4% of their body weight before discontinuation and lost an additional 1.3% over 2027. SciTechDaily
• $2.3 trillion of US healthcare spending annually is tied to conditions driven by metabolic risk such as type 2 diabetes, cardiovascular disease, osteoarthritis, sleep apnea, Alzheimer's and dementias, and more. RethinkX

Last updated: 02 August 2026